IDH2 and central nervous system cancer: Somatic mutations in IDH1 and IDH2 have been demonstrated in many human cancers including low grade glioma, glioblastoma, cholangiocarcinoma, chondrosarcoma, and acute myeloid leukemia as recently summarized [5].